Interrupting subcutaneous immunotherapy is not advised. Especially in potentially life‐threatening allergies, such as venom allergy, SCIT should be regularly continued. The possibility of expanding injection intervals in the continuation phase should be checked and may be beneficial.
Interrupting sublingual immunotherapy is not advised. Supply the patient with sufficient medication for a minimum of a 14 days quarantine.
Sublingual immunotherapy can be taken at home. The intake of SLIT by the patient at home or any place is advantageous in avoiding contact to potentially infected persons.
Both subcutaneous and sublingual immunotherapy can be continued in the current COVID‐19 pandemics, in any asymptomatic patients without suspicion for SARS‐CoV‐2 infection and/or contact to SARS‐CoV‐2‐positive individuals, in any patient with negative test result (RT‐PCR) or in any patient after an adequate quarantine or with detection of serum IgG to SARS‐CoV‐2 without virus‐specific IgM.
Preparedness of your Allergy clinic is imperative to cope with COVID‐19. Follow WHO guidelines and advice staff accordingly.
These recommendations are conditional since there is a paucity of data and they should be revised regularly with incoming new information on COVID‐19.